Table 4 Multivariable analyses of factors associated with hospital length of stay or costs among patients who survived at least 30 days
From: Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
Variable | Length of stay (LOS) (GLM gamma-identity link, N = 163) | Total cost (GLM gamma-log link, N = 162) | ||
|---|---|---|---|---|
β estimate (days) | 95% Wald CI for β estimate | Exp (β) estimate | 95% Wald CI for Exp (β) estimate | |
Antifungal Therapy | ||||
Other vs. voriconazole | 5.33 | (−3.43, 14.10) | 1.527 | (.996, 2.342) |
Echinocandins vs. voriconazole | −1.76 | (−7.76, 4.23) | .925 | (.729, 1.174) |
Mechanical Ventilation | 7.32 | (−.218, 14.87) | 1.854**** | (1.41, 2.44) |
Acute Renal Failure | 8.57 | (−1.08, 18.23) | 1.437** | (1.10, 1.87) |
Area | ||||
South vs. West | −3.08 | (−14.18, 8.03) | .591* | (.382, .917) |
Northeast vs. West | −4.88 | (−16.98, 7.23) | .558* | (.358, .872) |
Midwest vs. West | −4.27 | (−15.81, 7.28) | .588* | (.378, .913) |
APR-severity | 5.71 | (−0.68, 12.09) | 1.570* | (1.01, 2.24) |
Teaching Hospital | −1.25 | (−5.93, 3.43) | 1.015 | (.829, 1.242) |
Payer | ||||
Others vs. Medicare | -.712 | (−8.14, 6.71) | .964 | (.680, 1.37) |
Commercial-Indemnity vs. Medicare | -.814 | (−7.84, 6.21) | .860 | (.657, 1.12) |
Managed Care vs. Medicare | 4.34 | (−3.04, 11.71) | 1.603** | (1.16, 2.22) |
Medicaid vs. Medicare | 5.69 | (−8.06, 19.44) | 1.385 | (.963, 1.99) |
Timing of antifungal therapy1 | 1.28**** | (0.89, 1.67) | 1.035**** | (1.02, 1.05) |